We support oncology and hematology clinical projects globally – in every phase and virtually every indication, including supportive care.
Clinical Patients
58,400+Clinical Sites
14,900+Clinical Studies
310+Approved Drugs
19Our in-house oncology and hematology experts make the complex, simple. PRA's global project management and clinical operations team members have an average of 10+ years of study experience each.
Team members who possess direct oncology and hematology experience:
of our medical directors
of our directors and managers
of our CRAs
of our clinical team managers
Positioning ourselves as a leader in the immunotherapy space.
The immunotherapy space is advancing rapidly. That’s why we established a cross-functional expert group to keep pace with developments and apply best practices, standards, and expertise to our immuno-oncology trials in multiple treatment modalities, including cellular therapies, oncolytic viruses, cancer vaccines, checkpoint inhibitors, gut microbiome, and other novel approaches. We’ve collated our expertise into a centralized repository of standards and training, and we are streamlining best-in-class onboarding and continual training of our project teams to ensure our capabilities grow with the clinical research landscape.
Cancer Immunotherapy Patients
Cancer Immunotherapy Clinical Sites
Cancer Immunotherapy Studies
Non-clinical Projects
Leveraging evidence-based technology to target the right sites for the right patients.
We use evidence-based technology to target the appropriate geographic areas for oncology prevalence and identify a targeted list of investigators with the highest likelihood of accrual. Additionally, we leverage secondary health data such as the natural history of the disease, patient profiling, and key opinion leader identification for decision support in the design and execution of our clinical research studies.
See how strong site selection leads to enrollment success.Executing global studies locally.
Our global investigator network provides access to nearly all geographical areas for patient recruitment, including emergent markets such as Asia, Latin America, and Eastern Europe. However, it is our team’s practical knowledge of local regulations, standards of care, and cultural customs that enables us to maximize safety and efficiency in our oncology and hematology studies.
We’re proactively establishing preferred access to investigative sites able to deliver high-quality clinical data so that we can conduct accurate feasibility studies and more effectively recruit patients. This approach results in fast study start-ups and potentially reduced overall development timelines for our sponsors.
Explore related content and topics
Blog
Ask the Experts: How is the Medical Industry Currently Addressing Sickle Cell Disease?
Sickle Cell Disease (SCD) is a disease with few curative treatments that affects people globally. Both young and older patients who struggle with SCD…
Blog
ASH 2019 – Insights from our experts from the 61st American Society of Hematology (ASH) meeting
The American Society of Hematology (ASH) 2019 meeting, the world’s biggest hematology conference, addressed a number of new and exciting…
Blog
Bleeding Disorders: A Focus on Hemophilia and von Willebrand Disease
More than three million Americans are living with bleeding disorders. These disorders—including hemophilia, von Willebrand disease, and other rare…